pixatimod   Click here for help

GtoPdb Ligand ID: 9870

Synonyms: compound 18 [PMID: 22458531] | PG-545 | PG545
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Pixatimod (PG545) is a heparan sulphate mimetic that acts as an inhibitor of the heparanase enzyme [3-4]. Structurally it is a cholestanol-conjugated sulfated oligosaccharide.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 60
Hydrogen bond donors 13
Rotatable bonds 43
Topological polar surface area 1009.58
Molecular weight 2076.02
XLogP -14.66
No. Lipinski's rules broken 3
Click here for help
Canonical SMILES CC(CCCC(C1CCC2C1(C)CCC1C2CCC2C1(C)CCC(C2)OC1OC(COS(=O)(=O)O)C(C(C1OS(=O)(=O)O)OS(=O)(=O)O)OC1OC(COS(=O)(=O)O)C(C(C1OS(=O)(=O)O)OS(=O)(=O)O)OC1OC(COS(=O)(=O)O)C(C(C1OS(=O)(=O)O)OS(=O)(=O)O)OC1OC(COS(=O)(=O)O)C(C(C1OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)C)C
Isomeric SMILES CC(CCC[C@H]([C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)CC[C@@H](C2)O[C@@H]1O[C@H](COS(=O)(=O)O)[C@H]([C@@H]([C@H]1OS(=O)(=O)O)OS(=O)(=O)O)O[C@H]1O[C@H](COS(=O)(=O)O)[C@H]([C@@H]([C@H]1OS(=O)(=O)O)OS(=O)(=O)O)O[C@H]1O[C@H](COS(=O)(=O)O)[C@H]([C@@H]([C@H]1OS(=O)(=O)O)OS(=O)(=O)O)O[C@H]1O[C@H](COS(=O)(=O)O)[C@H]([C@@H]([C@H]1OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)C)C
InChI InChI=1S/C51H88O60S13/c1-22(2)7-6-8-23(3)27-11-12-28-26-10-9-24-17-25(13-15-50(24,4)29(26)14-16-51(27,28)5)95-46-42(108-121(79,80)81)38(104-117(67,68)69)34(30(96-46)18-91-112(52,53)54)100-47-43(109-122(82,83)84)39(105-118(70,71)72)35(31(97-47)19-92-113(55,56)57)101-48-44(110-123(85,86)87)40(106-119(73,74)75)36(32(98-48)20-93-114(58,59)60)102-49-45(111-124(88,89)90)41(107-120(76,77)78)37(103-116(64,65)66)33(99-49)21-94-115(61,62)63/h22-49H,6-21H2,1-5H3,(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)(H,64,65,66)(H,67,68,69)(H,70,71,72)(H,73,74,75)(H,76,77,78)(H,79,80,81)(H,82,83,84)(H,85,86,87)(H,88,89,90)/t23-,24+,25+,26+,27-,28+,29+,30-,31-,32-,33-,34-,35-,36-,37-,38+,39+,40+,41+,42-,43-,44-,45-,46-,47-,48-,49-,50+,51-/m1/s1
1. Brennan TV, Lin L, Brandstadter JD, Rendell VR, Dredge K, Huang X, Yang Y. (2016)
Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation.
J Clin Invest, 126 (1): 207-19. [PMID:26649979]
2. Dredge K, Brennan TV, Hammond E, Lickliter JD, Lin L, Bampton D, Handley P, Lankesheer F, Morrish G, Yang Y et al.. (2018)
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.
Br J Cancer, 118 (8): 1035-1041. [PMID:29531325]
3. Ferro V, Liu L, Johnstone KD, Wimmer N, Karoli T, Handley P, Rowley J, Dredge K, Li CP, Hammond E et al.. (2012)
Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis.
J Med Chem, 55 (8): 3804-13. [PMID:22458531]
4. Hammond E, Handley P, Dredge K, Bytheway I. (2013)
Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues.
FEBS Open Bio, 3: 346-51. [PMID:24251094]
5. Putz EM, Mayfosh AJ, Kos K, Barkauskas DS, Nakamura K, Town L, Goodall KJ, Yee DY, Poon IK, Baschuk N et al.. (2017)
NK cell heparanase controls tumor invasion and immune surveillance.
J Clin Invest, 127 (7): 2777-2788. [PMID:28581441]